Our Mission
Our mission is to detect cancer early, when it can be cured. We are working to change the trajectory of cancer mortality and bring stakeholders together to adopt innovative, safe and effective technologies that can transform cancer screening.
The Galleri test is a first-of-its-kind multi-cancer early detection (MCED) test that can help screen for many of the deadliest cancers that don’t have recommended screening today.
The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur.
Multi-cancer early detection (MCED) blood tests analyze DNA that has been shed into the bloodstream by all cells growing in the body, including cancer cells.
GRAIL’s Methylation Platform preferentially targets the most informative regions of the genome and uses machine-learning algorithms to detect methylation patterns associated with cancer and, when found, predict the cancer signal origin.
Who We Are
GRAIL is a healthcare company innovating to solve healthcare’s most important challenges. Our team of leading scientists, engineers and clinicians are on an urgent mission to detect cancer early, when it may be more treatable and potentially curable.
